BioInsights - Next steps for MSC innovation

Next steps for MSC innovation

Cell & Gene Therapy Insights 2023; 9(1), 11–17

DOI: 10.18609/cgti.2023.002

Published: 18 January 2023
Jacques Galipeau

David McCall, Commissioning Editor, BioInsights, talks to Jacques Galipeau, Associate Dean for Therapeutics Development at University of Wisconsin-Madison, and President of the International Society for Cell & Gene Therapy (ISCT)

Jacques Galipeau, MD FRCP(C) is the Don and Marilyn Anderson Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin in Madison, and is Associate Dean for Therapeutics Development at the University of Wisconsin School of Medicine & Public Health. He is the director of the University of Wisconsin Advanced Cell Therapy Program whose mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of UW cell therapy innovations to improve outcomes for children and adults. Dr Galipeau leads a research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He has also developed the field of fusion engineered cytokines known as fusokines, as a novel pharmaceutical means of treating immune disorders and cancer. He is an internationally recognized expert in translational development of cellular pharmaceuticals and the sponsor of a series of FDA-sanctioned clinical trials examining the use of personalized cell therapies.